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ABSTRACT
Zollinger–Ellison syndrome is a functional neuroendocrine tumor with inappropriate gastrin secretion and hyperchlorhydria
causing severe peptic ulcer disease and chronic diarrhea. Although 70% of primary gastrinomas occur in the region of the duodenum,
the diagnosis and localization of gastrinomas can be challenging because of small lesions that may arise functionally as lymph node
metastases at initial presentation. We report a 76-year-old woman presenting with Zollinger–Ellison syndrome several months after
surgical resection of endometrioid small cell neuroendocrine carcinoma and endometrioid adenocarcinoma.

INTRODUCTION
The diagnosis of Zollinger–Ellison syndrome (ZE) can be challenging. Common sites for primary gastrinoma include the duodenum
and pancreatic/peripancreatic region,1,2 but there is a paucity of information regarding ZE arising in the context of gynecologic
cancer. One case series reported 25 cases of endometrial neuroendocrine tumors, of which 15 were associated with endometrioid
adenocarcinoma, and 4 were small cell neuroendocrine tumors mixed with endometrioid adenocarcinoma.3 Here, we report a case of
delayed presentation of gastrinoma in a patient with a coexisting endometrioid small cell neuroendocrine carcinoma and endometrioid adenocarcinoma.

CASE REPORT
A 76-year-old white woman presented initially with heavy vaginal bleeding. Enhanced computerized tomography (CT) scan
revealed an enlarged uterus measuring 6.2 3 5.4 cm. The patient underwent uneventful robotic-assisted total laparoscopic hysterectomy with bilateral salpingo-oophorectomy and bilateral sentinel lymph node dissection. Pathological examination revealed
stage IB mixed endometrioid adenocarcinoma and small cell neuroendocrine carcinoma. Gastrin immunostaining was negative in
all tissue examined (both small cells and endometroid carcinoma). Four cycles of cisplatin 50 mg/m2 and etoposide 80 mg/m2 were
given as standard chemotherapy for International Federation Of Gynecology And Obstetrics grade 2 endometrial cancer followed by
radiation treatment with brachytherapy. International Federation Of Gynecology And Obstetrics Grading System is validated
international federation of gynecology and obstetrics system used for endometrial cancer staging.4
The patient presented 3 months after completing chemotherapy (1 month after radiation treatment with brachytherapy) with
melena in addition to chronic watery diarrhea. The patient denied aspirin or nonsteroidal anti-inﬂammatory drug use and was not
taking a proton pump inhibitor (PPI) for the past 12 months. The patient denied a history of either gastrointestinal bleeding or
abdominal pain. Esophagogastroduodenoscopy demonstrated multiple nonbleeding superﬁcial gastric ulcers with clean ulcer bases
(Forrest Class III) in the gastric antrum and prepyloric region (Figure 1). There were no ulcers identiﬁed in the duodenum (Figure 2).
Gastric pH was not obtained at this examination. Serum gastrin level was obtained because of clinical suspicion for potential ZE in the
setting of multiple gastric ulcers without signiﬁcant risk factors for peptic ulcer disease. An elevated serum gastrin level (538 pg/mL)
was noted on the day after esophagogastroduodenoscopy with the patient not on PPI therapy. Somatostatin receptor-based imaging
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Figure 1. Multiple nonbleeding superficial gastric ulcers with clean
ulcer bases (Forrest Class III) in the gastric antrum and prepyloric
region.

(Ga-68 Dotatate-positron emission tomography [PET]/CT)
revealed avid left paraesophageal node uptake measuring 11 3
8 mm (Figure 3). The patient was started on pantoprazole 40 mg
twice a day. Stool Helicobacter pylori antigen test was negative.
Serum calcium (9.2 mg/dL), renal function, and parathyroid
hormone were within normal limits.
After 5 months, follow-up upper endoscopic examination
demonstrated 2 persistent (2–3 mm) clean-based ulcerations in
the gastric antrum on the posterior gastric wall (Figures 4 and
5). Gastric ﬂuid demonstrated pH of 1 despite taking pantoprazole 40 mg twice a day for 4 months. Endoscopic ultrasound examination demonstrated an ill-deﬁned 14 3 70-mm
heterogenous lymph node in the approximate location of the
lymph node noted on the PET scan which was sampled by ﬁneneedle aspiration, revealing scant lymphoid tissue insufﬁcient
for pathologic diagnosis (Figure 6).
The diagnosis of ZE was supported by elevated serum gastrin (538
pg/mL) and abnormal somatostatin receptor scan uptake with
gastric pH , 2 and persistent gastric ulcers despite high-dose PPI
for more than 2 months. Unfortunately, the tissue sampling from
the left paraesophageal node yielded insufﬁcient material for
microscopic examination. Somatostatin receptor-Dotatate-PET/
CT scan showed no abnormal uptake elsewhere, and we speculate
that the primary lymph node represents the primary gastrinoma
site. The patient’s chronic diarrhea and endoscopic appearance of
her gastric ulcers substantially improved after high-dose PPI
therapy. Follow-up gastrin level was trending down (307 pg/mL)
after 4 months of PPI therapy as of May 2020.
Our patient elected to pursue medical management because of
her advanced age and multiple comorbidities, including
endometroid tumor, recent radiation and chemotherapy exposure, body mass index of 41.9 kg/m2, and type 2 diabetes. Our
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Figure 2. Normal endoscopic duodenal examination.

patient is scheduled for follow-up visits with biochemical laboratory studies including fasting serum vitamin B 12, ionized
calcium, parathyroid hormone, and gastrin levels every 3–6
months. Surveillance imaging studies (abdominal CT or magnetic resonance imaging) will be conducted annually, with somatostatin receptor scintigraphy repeated at least every 3 years.5

DISCUSSION
Here, we describe a case of ZE presenting several months after
surgical resection of endometrioid small cell neuroendocrine
carcinoma and endometrioid adenocarcinoma.
Primary gastrinoma is frequently detected as lymph node metastasis at ﬁrst presentation and often within a lymph node in
the “gastrinoma triangle.”1,6 Other primary gastinoma sites
include stomach, mesentery, ovaries, heart, lung, hepatobiliary
tract, and jejunum.1,6 In cases where the tumor can be localized,
surgical exploration may increase diagnostic yield, prevent
advanced disease progression, and improved survival rate.7
Most guidelines for evaluation for patients with suspected ZE
recommend obtaining fasting serum gastrin (off PPI) followed
by gastric pH measurement. The accepted criteria for a diagnosis of ZE include fasting serum gastrin more than 10-fold
above normal (,100 pg/mL) and a gastric pH ,2.7,8 The lack of
consistency in establishing standardized ZE criteria primarily
reﬂects widespread use of PPIs and limited access to gastric pH
testing.9 In patients with limited access for gastric acid assessment, alternative criteria include active ulcer disease combined
with positive somatostatin receptor scintigraphy, cytology or
biopsy for neuroendocrine tumor, or a positive secretin test.9 In
some cases, diarrhea responsive to PPI or histamine H2 receptor
antagonist therapy may be an adjunctive criterion.9
Long-term acid suppression is recommended in ZE patients to
prevent severe peptic ulcer disease.5 In sporadic ZE patients
acgcasereports.com 2
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Figure 3. Somatostatin receptor-based imaging (Ga-68 Dotatate-positron emission tomography/computerized tomography) revealed avid left
paraesophageal node uptake measuring 11 3 8 mm.

without multiple endocrine neoplasia, type 1, current
guidelines recommend surgical exploration for complete
tumor removal if possible, in patients without medical contraindication.4,10 In a single institution experience, there was
no signiﬁcant difference in survival between subjects with
primary lymph node vs nonprimary lymph node gastrinomas. In addition, patients with primary lymph node
gastrinoma were less likely to develop persistent/recurrent
disease (9.1% vs 42.9%, P 5 .04).11 In our case, the decision to
pursue medical management reﬂected the patients’ limited
life expectancy and her medical comorbidities, including
(recent history of endometrioid tumor, chemoradiation exposure, obesity, and type 2 diabetes). In general, however,
primary tumor localization is an important step to determine
whether surgical resection is feasible,5 and somatostatin
receptor-based imaging, and endoscopic ultrasonography
may guide localization of the primary site and determining
metastatic burden.10,12
To the best of our knowledge, the coincidence of multiple
neuroendocrine neoplasms involving the gastrointestinal tract
and endometrium has not been described. Owing to its variable

Figure 4. Persistent clean-based ulcerations in the gastric antrum
on the posterior gastric wall.
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clinical presentation, high mortality, and challenging primary
lesion identiﬁcation, clinicians should consider ZE as a potential diagnosis in a patient with multiple gastric or duodenal
ulcers. In addition, it is essential to consider the possibility of ZE
even in complex situations such as our patient because of the
potential to change therapeutic strategies and its impact on the
overall prognosis. In our case, the presumptive diagnosis of ZE
was based on a combination of fasting serum gastrin concentration, gastric pH, and somatostatin receptor–based imaging.
Our case reﬂects the challenges in establishing a diagnosis of ZE
without formally identifying a primary lesion. ZE should be
considered in a patient with NET presenting with melena and
diarrhea but without evident risk factors for gastrointestinal
bleeding or Helicobacter pylori infection.
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Figure 5. Persistent clean-based ulcerations in the gastric antrum
on the posterior gastric wall.
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Figure 6. Ill-defined 14 3 7-mm heterogenous lymph node/endoscopic ultrasound examination.
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